Up­ping ex­pec­ta­tions, Sanofi makes its case on why Dupix­ent will go on to $14.5B in peak sales — what­ev­er Eli Lil­ly may have on its mind

Over the week­end, Eli Lil­ly laid out some sol­id Phase III rea­sons why the phar­ma gi­ant thinks it can take on Re­gen­eron and Sanofi’s Dupix­ent on the se­vere atopic der­mati­tis front. But no one at Sanofi ap­pears to have been lis­ten­ing very se­ri­ous­ly.

Mon­day night the Paris-based multi­na­tion­al laid out its case for why Dupix­ent will be one of the biggest drug fran­chis­es in bio­phar­ma his­to­ry. And Sanofi CEO Paul Hud­son made that very clear by promis­ing their drug will go on to mar­ket­ing his­to­ry with about $14.5 bil­lion in peak sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER